Radiopharm Theranostics
RADX
7 hedge funds and large institutions have $2.06M invested in Radiopharm Theranostics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.
1.96% less ownership
Funds ownership: 436.26% → 434.3% (-2%)
36% less funds holding
Funds holding: 11 → 7 (-4)
44% less capital invested
Capital invested by funds: $3.67M → $2.06M (-$1.61M)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$562 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
-$637K |
| 2 |
RP
Regal Partners
Sydney, NSW,
Australia
|
-$248K |
| 3 |
VF
Virtu Financial
New York
|
-$76K |
| 4 |
Jane Street
New York
|
-$75.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$55.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
1
Silverarc Capital Management
Boston,
Massachusetts
| $806K | – | – | – |
|
|
SCM
2
Stonepine Capital Management
Bend,
Oregon
| $739K | – | – | – |
|
|
3
HSBC Holdings
London,
United Kingdom
| $265K | -$637K | -130,252 | -68% |
|
|
RP
4
Regal Partners
Sydney, NSW,
Australia
| $173K | -$248K | -50,771 | -56% |
|
5
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $68.8K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $12.9K | -$55.1K | -11,277 | -79% |
|
|
7
RhumbLine Advisers
Boston,
Massachusetts
| $519 | +$562 | +115 | +1,917% |
|
|
VF
8
Virtu Financial
New York
| – | -$76K | -14,591 | Closed |
|
|
9
Jane Street
New York
| – | -$75.5K | -14,469 | Closed |
|
|
MG
10
Marex Group
London,
| – | -$53.7K | -10,285 | Closed |
|
|
SWP
11
Strategic Wealth Partners
Independence,
Ohio
| – | -$52 | -10 | Closed |
|
RADX Hedge Fund Activity: Q1 2026 in Review
7 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Radiopharm Theranostics (RADX) for Q1 2026, worth a combined $2.06M — down 44% from $3.67M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of RADX and 0 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was RhumbLine Advisers, adding an estimated $562. The largest seller was HSBC Holdings, cutting an estimated $637K.
- 7 institutional investors held Radiopharm Theranostics (RADX) as of Q1 2026, down from 11 in Q4 2025.
- Funds reported $2.06M of Radiopharm Theranostics stock for Q1 2026, down 44% quarter-over-quarter.
- 0 funds opened new Radiopharm Theranostics positions in Q1 2026 and 4 closed out, a net change of -4 holders.
- The largest Radiopharm Theranostics buyer in Q1 2026 was RhumbLine Advisers, an estimated $562 added.
- The largest Radiopharm Theranostics seller in Q1 2026 was HSBC Holdings, an estimated $637K sold.
Based on aggregated 13F filings for Q1 2026.